Neural stem cell therapy - TheraBiologicsAlternative Names: HB1.F3.CD neural stem cells; TBio-01; TBX-01; TBX.CD + 5-FC; TBX.CE + irinotecan; TBX.CE NSCs + IRN SN-38
Latest Information Update: 20 Apr 2016
At a glance
- Originator TheraBiologics
- Developer City of Hope National Medical Center; TheraBiologics
- Class Stem cell therapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioma